Läkemedelsföretaget Moberg Derma gör alltjämt förlust men förbättrade ändå sitt resultat kraftigt till -6,4 miljoner kronor, vilket kan jämföras med resultatet för 2010 som var -31 miljoner kronor. Omsättningen har ökat från 8,5 miljoner kronor under 2010, till 55,9 miljoner kronor 2011. Årets sista kvartal gjorde företaget en vinst på 4,4 miljoner kronor. Resultatet per aktie uppgick till - 0,82 kronor och kassan var 74.1 miljoner kronor vid årets slut.
Under året gjordes två nyemissioner, en fulltecknad i samband med att företaget noterades på Nasdaq OMX Stockholm i slutet av maj, med teckningskursen 29 kronor, och en i mars. De båda emissionerna inbringade företaget 81 miljoner kronor.
I september tecknades ett licensavtal med Meda för marknadsföring av nagelbehandlingsmedlet Nalox. Avtalet är värt totalt 32 miljoner kronor, varav 19 miljoner kronor fås vid uppnådda föräljningsmål. Avtalet med Meda utökades till ännu fler länder under fjärde kvartalet ovilket ger ytterligare 18 miljoner kronor.
Nalox fick positiva resultat i en klinisk studie som omfattade 75 patienter med nagelsvamp. Studien visade att 92 procent av patienterna förbättrades efter åtta veckors behandling.
Enligt årsrapporten kommer fokus under 2012 kommer att vara att stödja bolagets distributörer för att möjliggöra en framgångsrik lansering av Nalox. Företagets bedömning är att omsättningstillväxten kommer fortsätta.
Under året gjordes två nyemissioner, en fulltecknad i samband med att företaget noterades på Nasdaq OMX Stockholm i slutet av maj, med teckningskursen 29 kronor, och en i mars. De båda emissionerna inbringade företaget 81 miljoner kronor.
I september tecknades ett licensavtal med Meda för marknadsföring av nagelbehandlingsmedlet Nalox. Avtalet är värt totalt 32 miljoner kronor, varav 19 miljoner kronor fås vid uppnådda föräljningsmål. Avtalet med Meda utökades till ännu fler länder under fjärde kvartalet ovilket ger ytterligare 18 miljoner kronor.
Nalox fick positiva resultat i en klinisk studie som omfattade 75 patienter med nagelsvamp. Studien visade att 92 procent av patienterna förbättrades efter åtta veckors behandling.
Enligt årsrapporten kommer fokus under 2012 kommer att vara att stödja bolagets distributörer för att möjliggöra en framgångsrik lansering av Nalox. Företagets bedömning är att omsättningstillväxten kommer fortsätta.
"To become an internationally leading dental company with innovative, proprietary products of high therapeutic and commercial value." 
"Allenex is a life science company that develops, manufactures, markets and sells high quality products for the transplantation market." 
"Your global partner of pharmaceutical service and cGMP manufacturing" 
"Anton Paar is a product and service leader in the field of scientific instruments. We deliver uncompromised quality in everything we do." 
"Our reliability, customer service, global network and integrated technology make World Courier service truly "A service no one else can deliver"." 
"To supply Swedish and Danish laboratories with laboratory equipment and furniture of highest quality and offer service on all delivered products." 
"We help our clients create significant business value through scientific expertise." 
"We have a unique technological platform, built around 5HT-receptor antagonism, for the treatment of inflammation and pain"." 
"With our first class products and our committed and skilled colleagues we guarantee our customers the best support in the market, at no extra charge." 
"Mercodia has been a supplier of reliable assays since 1991" 
"The PolyPeptide Group is a world class manufacturer of peptide active pharmaceutical ingredients." 
"TFS is today the leading European development partner for biopharmaceutical companies in their global clinical development process." 
"Our products enable an increased number of transplants leading to substantial cost savings for society and increased quality of life for patients." 
"Our goal is to invest in innovations and develop new unique pharmaceuticals" 
"Together with Zacco our clients achieve their business goals through the management of their intellectual property." 
"Dilafor is developing new products in the field of obstetrics, to provide an effective solution to the challenge of dystocia or protracted labor"
" 
"Discover your possibilities in one of Europe´s most productive life science regions. Welcome to Stockholm-Uppsala."
" 
"We turn medical research into applications for better health and well-being." 
"To adapt Competent Authorities´ requirements into opportunities is not just an artform - today it´s a business necessity." 
"Medivir is a specialty pharmaceutical company with unique positioning on the Nordic market and our goal is become a profitable company in high growth" 
"Innovation takes place when biology meets engineering; ICT is an enabler to solve the needs for increased functionality and reduced cost in Life Science" 
"Our aim is to be the best drug development partner to the biotechnology and pharmaceutical industry no matter where you are based." 
"We are entirely devoted to luminescence technology." 
"APL provides high-quality services to Life Science. We are a Dedicated Partner from Discovery to Market." 
"Best in class companies see the value of optimising their business by having an effective strategy for information management and documentation." 
"To develop innovative and effective pharmaceuticals within autoimmune/ inflammatory diseases and cancer where major medical need exists" 
"PCG - a professional full service CRO for your clinical trials.
Powered by Viedoc, globally trusted eCRF, keeping trials within budget and timelines" 
"Our vision is to become one of the top 10 global providers of scientific instruments; we will get there by striving for market leadership in our respective product and application niches."
" 
"We promise to go the extra mile every day to ensure you receive the highest level of service and value with each shipment you entrust to us." 
"Uppsala BIO is a life science pathfinder. We build ways to make life science flourish, in cooperation with industry, academia, society and healthcare." 
"To be acknowledged as the Best-in-Class provider of pharmaceutical development and manufacturing services by customers, employees & other stakeholders" 
"We are recognized as a flexible partner with short decision and lead times plus a proven record for the highest quality and cost efficiency." 
"To be the most attractive node and business platform in the Nordic countries for new and innovative Life Science companies" 
"Our services in ligand-based and structure-based drug design is a cost-efficient alternative for smaller pharmaceutical companies" 
"As a full service CRO with offices in all Nordic countries we can provide our customer with professional support throughout the clinical research." 
"Novel products for CVD treatment and prevention." 
"We offer effective staffing solutions provided by specialists, we understand a company’s specific needs and we know where to find the best talent." 
"Our organisation value is to contribute to positioning Scandinavian healthcare and research in absolute world class." 
"We are making it more attractive for companies to invest in innovation with reduced corporation tax on profits from patents to 10%." 
"VWR is a global laboratory distributor of chemicals, life science products, consumables, equipment, instruments, furniture, e-commerce and services" 
"We aim to be the pioneering benchmark in user-friendly software experience in combination with the highest level of quality." 
"Your work is important to us, we are committed to your success.
Innovative tools? Please download the Promega app." 
